Advanced search
Start date
Betweenand
Related content
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Efficacy and Safety of Botulinum Toxin Type A on Persistent Myofascial Pain: A Randomized Clinical Trial

Full text
Author(s):
Canales, Giancarlo De la Torre [1] ; Alvarez-Pinzon, Natalia [1] ; Manuel Munoz-Lora, Victor Ricardo [1] ; Peroni, Leonardo Vieira [2] ; Gomes, Amanda Farias [2] ; Sanchez-Ayala, Alfonso [3] ; Haiter-Neto, Francisco [2] ; Manfredini, Daniele [4] ; Rizzatti-Barbosa, Celia Marisa [1]
Total Authors: 9
Affiliation:
[1] Univ Estadual Campinas, Piracicaba Dent Sch, Dept Prosthodont & Periodontol, BR-13414903 Sao Paulo - Brazil
[2] Univ Estadual Campinas, Piracicaba Dent Sch, Dept Oral Diag, BR-13414903 Sao Paulo - Brazil
[3] Univ Estadual Ponta Grossa, Dept Dent, BR-84030900 Ponta Grossa, Parana - Brazil
[4] Univ Siena, Dept Dent, I-53100 Siena - Italy
Total Affiliations: 4
Document type: Journal article
Source: TOXINS; v. 12, n. 6 JUN 2020.
Web of Science Citations: 0
Abstract

This study assessed the safety and efficacy of three different doses of BoNT-A for persistent myofascial pain (MFP). One hundred female subjects were randomly assigned into five groups (n= 20): oral appliance (OA), saline solution (SS) and three BoNT-A groups with different doses. Pain intensity and pressure pain threshold were evaluated up to 24 weeks after treatment. Adverse effects related to muscle contraction, masticatory performance, muscle thickness and mandibular bone volume were also assessed. Changes over time were compared within and between groups. The ``nparLD{''} package and Wilcoxon signed-rank test were used to analyze the data. BoNT-A reduced pain intensity (p< 0.0001) and increased pressure pain threshold (p< 0.0001) for up to 24 weeks compared to the placebo. No differences were found between BoNT-A and OA at the last follow-up. A transient decline in masticatory performance (p< 0.05) and muscle contraction (p< 0.0001), and a decrease in muscle thickness (p< 0.05) and coronoid and condylar process bone volume (p< 0.05) were found as dose-related adverse effects of BoNT-A. Regardless of the dose, BoNT-A was as effective as OA on MFP. Notwithstanding, due to BoNT-A dose-related adverse effects, we suggest the use of low doses of BoNT-A in MFP patients that do not benefit from conservative treatments. (AU)

FAPESP's process: 14/15863-7 - Comparison of conventional and BontA treatments in patients with myogenic temporomandibular disorders and chronic pain
Grantee:Celia Marisa Rizzatti Barbosa
Support Opportunities: Regular Research Grants